# Eikon Therapeutics, Inc.: overview EIKN · Nasdaq · CIK 1861123 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/eikn.md) · [Financials](/companies/eikn/financials.md) · [Filings](/companies/eikn/filings.md) · [Insiders](/companies/eikn/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(26.91)](/filings/0001193125-26-216791.md) | [(36.94)](/filings/0001193125-26-349185.md) | [(2.46)](/filings/0001193125-26-216791.md) | [(1.63)](/filings/0001193125-26-349185.md) | | Free cash flow | $m | [(76.9)](/filings/0001193125-26-216791.md) | [(54.5) d](/filings/0001193125-26-349185.md) | [(90.1)](/filings/0001193125-26-216791.md) | [(65.2) d](/filings/0001193125-26-349185.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure. ## Last five fiscal years Not reported. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/eikn/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $65.2m | 4,993,906 | | Added +1,157,076 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $55.9m | 4,281,425 | | Added +962,046 | | [Foresite Capital Management IV, LLC](/funds/1704132.md) | 2026-06-30 | $25.4m | 1,943,682 | | Unchanged | | [Merck & Co., Inc.](/funds/310158.md) | 2026-06-30 | $21.7m | 1,666,666 | | Unchanged | | [Foresite Capital Management V, LLC](/funds/1792206.md) | 2026-06-30 | $17.2m | 1,318,983 | | Unchanged | | [Capital World Investors](/funds/1422849.md) | 2026-06-30 | $15.3m | 1,175,944 | | Added +32,307 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $12.0m | 922,707 | | Reduced −46,724 | | [EcoR1 Capital, LLC](/funds/1587114.md) | 2026-06-30 | $9.6m | 732,606 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $7.3m | 556,955 | | Added +283,024 | | [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $7.2m | 555,555 | | Unchanged | ## Recent filings [All 66 filings](/companies/eikn/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 09:15 ET | [8-K](/filings/0001193125-26-429549.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-429549 | | 2026-08-14 | 20:44 ET | [8-K](/filings/0001193125-26-349936.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-349936 | | 2026-08-13 | 16:10 ET | [10-Q](/filings/0001193125-26-349185.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349185 | | 2026-08-13 | 16:06 ET | [8-K](/filings/0001193125-26-349154.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-349154 | | 2026-08-03 | 16:39 ET | [8-K](/filings/0001193125-26-330710.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-330710 | | 2026-06-10 | 16:15 ET | [8-K](/filings/0001193125-26-265861.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-265861 | | 2026-06-01 | 07:30 ET | [8-K](/filings/0001193125-26-249725.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-249725 | | 2026-05-11 | 16:13 ET | [10-Q](/filings/0001193125-26-216791.md) | Quarterly report, period 2026-03-31 | 0001193125-26-216791 | | 2026-05-11 | 16:05 ET | [8-K](/filings/0001193125-26-216744.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-216744 | | 2026-03-30 | 08:02 ET | [8-K](/filings/0001193125-26-130449.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-130449 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-130395.md), filed Mar 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1861123 - Tickers: EIKN - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 06:02 ET. No prices; not investment advice.